Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19110509 | 0.98 | LTA4H (0.46) | KMT2ANPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL23574239 | 0.95 | SLC6A2 (0.44) | KMT2ANPC1RAB9ASLC6A2SLC6A4 | |
| SCHEMBL1119520 | 0.91 | SLC6A2 (0.46) | SLC6A2SLC6A4GBA1 | |
| Ammonia Solution, Strong SCHEMBL987776 | 0.88 | SLC6A2 (0.45) | SLC6A2SLC6A4GBA1 | |
| SCHEMBL578602 | 0.81 | GBA1 (0.66) | SLC6A2SLC6A4HRH3GBA1 | |
| SCHEMBL24622493 | 0.81 | SLC6A2 (0.41) | SLC6A2SLC6A4GBA1 | |
| SCHEMBL2090678 | 0.81 | SLC6A2 (0.41) | SLC6A2SLC6A4GBA1 | |
| SCHEMBL578726 | 0.78 | SLC6A2 (0.52) | SLC6A2SLC6A4 | |
| SCHEMBL18404400 | 0.77 | LTA4H (0.44) | SLC6A2SLC6A4LTA4HHRH3GBA1 | |
| SCHEMBL14278032 | 0.77 | LTA4H (0.44) | LTA4HHRH3GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4065230-A1 | THERAPEUTIC COMPOUNDS | Genentech, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-114786778-A | Therapeutic compounds | 基因泰克公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021108483-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| CN-110642669-A | Preparation method of para-substituted bromobenzene | 上海博栋化学科技有限公司 | 2020-01-03 | — | — | CN | disclosed |
| US-6673824-B1 | HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| US-6107320-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 2000-08-22 | — | — | US | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002396-A1 | THERAPEUTIC COMPOUNDS | YAP1, YES1, TEAD2 | KMT2A 3482/4885NPC1 658/4885RAB9A 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.